ALG-009 is a small molecule commercialized by Aligos Therapeutics, with a leading Phase II program in Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ALG-009’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for ALG-009 is expected to reach an annual total of $23 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ALG-009 Overview

ALG-055009 is under development for the treatment of non-alcoholic steatohepatitis (NASH). The drug candidate act by targeting thyroid hormone receptor beta (THR-beta). It is administered orally.

Aligos Therapeutics Overview

Aligos Therapeutics (Aligos) is a clinical-stage biopharmaceutical company developments therapeutics for liver and viral diseases. The company pipeline products include ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist for metabolic dysfunction-associated steatohepatitis (MASH), and ALG-000184, a small molecule capsid assembly modulator for chronic hepatitis b (CHB). Aligo’s other pipeline products include ALG-097558 and ALG-125755. The company collaborates with various research institutes and biotech companies for drug development. It operates its offices in Belgium, the US and China. Aligos in headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$15.5 million for the fiscal year ended December 2023 (FY2023), an increase of 11.7% over FY2022. The operating loss of the company was US$88.1 million in FY2023, compared to an operating loss of US$97.6 million in FY2022. The net loss of the company was US$87.7 million in FY2023, compared to a net loss of US$96.1 million in FY2022. The company reported revenues of US$1 million for the first quarter ended March 2024, a decrease of 63.2% over the previous quarter.

For a complete picture of ALG-009’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.